Clinical INFI HIV.gov THE JOURNAL OF INFECTIOUS
Post# of 148279
(Total Views: 566)
Posted On: 08/06/2023 7:18:17 PM
Clinical INFI HIV.gov
THE JOURNAL OF INFECTIOUS DISEASES (2010) showed that Leronlimab had substantial and prolonged activity against HIV. ...
Antiviral response increased as the total amount of Leronlimab administered over the treatment period INCREASED.
___________________________________________________________________
Studies indicate that Leronlimab may be effective against R5-Tropiv Virus that is resistant to Maraviroc...(aka Selzentry).
___________________________________________________________________
Results published in HIV Clinical Trials (2018) showed that in the CD01 study 23 out of 41 participants (56.1%) maintained Viral Suppression throughout the (12) week Monotheraphy treatment phase. (18) participants did Not maintain suppression during the treatment phase.
___________________________________________________________________
Results published in (PLos Patogens (2022) showed in the CD01 extension study (5) participants have maintained Viral suppression on Leronlimab Monotheraphy for over (7) years.
__________________________________________________________________
Results from the CD2 trial presented @ ASM Microbe (2019) showed that 64% of participants who received a SINGLE subcutaneous dose of Leronlimab had a SIGNIFICANT reduction in Viral Load Levels from baseline after (1) week,...as compared to 34% of participants who received placebo.
__________________________________________________________________
Preliminary results presented @ CROI 2019 indicated that the majority of participants that received Higher weekly subcutaneous doses of Leronlimab (525 mg and 700mg) were able to maintain Viral Suppression.
Did someone say SAFETY?
THE JOURNAL OF INFECTIOUS DISEASES (2010) showed that Leronlimab had substantial and prolonged activity against HIV. ...
Antiviral response increased as the total amount of Leronlimab administered over the treatment period INCREASED.
___________________________________________________________________
Studies indicate that Leronlimab may be effective against R5-Tropiv Virus that is resistant to Maraviroc...(aka Selzentry).
___________________________________________________________________
Results published in HIV Clinical Trials (2018) showed that in the CD01 study 23 out of 41 participants (56.1%) maintained Viral Suppression throughout the (12) week Monotheraphy treatment phase. (18) participants did Not maintain suppression during the treatment phase.
___________________________________________________________________
Results published in (PLos Patogens (2022) showed in the CD01 extension study (5) participants have maintained Viral suppression on Leronlimab Monotheraphy for over (7) years.
__________________________________________________________________
Results from the CD2 trial presented @ ASM Microbe (2019) showed that 64% of participants who received a SINGLE subcutaneous dose of Leronlimab had a SIGNIFICANT reduction in Viral Load Levels from baseline after (1) week,...as compared to 34% of participants who received placebo.
__________________________________________________________________
Preliminary results presented @ CROI 2019 indicated that the majority of participants that received Higher weekly subcutaneous doses of Leronlimab (525 mg and 700mg) were able to maintain Viral Suppression.
Did someone say SAFETY?
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼